Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
July 21st, 2018
19.2K views
In this protocol, we describe how to utilize [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (18F-FDG PET/CT) imaging to measure the tumor metabolic response to the targeted therapy MLN0128 in a Kras/Lkb1 mutant mouse model of lung cancer and coupled imaging with high resolution ex vivo autoradiography and quantitative histology.
Overview
This protocol outlines the use of [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (18F-FDG PET/CT) imaging to assess tumor metabolic responses to the targeted therapy MLN0128 in a Kras/Lkb1 mutant mouse model of lung cancer. It emphasizes the importance of non-invasive imaging techniques for understanding tumor metabolism during therapeutic interventions.
Key Study Components
Area of Science
- Cancer metabolism
- Cancer therapeutics
Background
- Understanding tumor metabolism is crucial for developing effective cancer therapies.
- Non-invasive imaging allows for real-time monitoring of tumor responses to treatments.
- The study utilizes a mouse model with specific genetic mutations relevant to lung cancer.
Purpose of Study
- To measure the metabolic response of tumors to targeted therapy.
- To explore the correlation between tumor metabolism and therapeutic efficacy.
- To establish a reliable imaging protocol for future studies.
Methods Used
- Preparation of mice and administration of fluorine-18 labeled fluoro-deoxyglucose.
- Non-invasive imaging using PET/CT scans to visualize tumor metabolism.
- Quantitative histology and autoradiography for detailed analysis.
- Data analysis using AMOD software to assess injected dose and tumor uptake.
Main Results
- High glycolytic activity observed in tumors with KRAS and LKB1 co-mutations.
- Correlation between glucose transporter expression and FDG uptake.
- Demonstrated reproducibility of imaging results under controlled conditions.
Conclusions
- The protocol provides a framework for studying tumor metabolism in vivo.
- Findings contribute to understanding the impact of therapies on tumor growth.
- Future applications may include other PET tracers for diverse biological processes.
Frequently Asked Questions
What is the significance of using PET/CT imaging in this study?
PET/CT imaging allows for non-invasive monitoring of tumor metabolism over time, providing insights into the effectiveness of therapeutic interventions.
How does the method ensure reproducibility?
By maintaining consistent animal handling conditions such as anesthesia, warming, and fasting, the method aims to produce reliable and reproducible results.
What are the implications of high glycolytic activity in tumors?
High glycolytic activity may indicate aggressive tumor behavior and can inform treatment strategies targeting metabolic pathways.
What precautions should be taken when handling radioactivity?
Protective equipment should be used, and all applicable regulatory procedures must be followed to ensure safety when handling radioactive materials.
Can this method be applied to other types of cancer?
Yes, the imaging protocol can be adapted to study various biological processes in different cancer models using other PET tracers.
Executive Industry Relevance
Dynamic measurement of glucose metabolism using 18F-FDG PET/CT and quantitative histology in genetically engineered mouse models enables non-invasive, real-time assessment of therapeutic response in lung cancer. This integrated approach supports predictive confidence in evaluating metabolic pathway modulation and informs early-stage portfolio decisions for targeted therapies. The method enhances translational continuity by linking in vivo imaging with ex vivo biomarker quantification.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of metabolic pathway dependencies in genetically defined tumor models.
- Supports functional validation of mTOR pathway inhibition through quantitative imaging and histology.
- Facilitates predictive de-risking by correlating biomarker changes with metabolic imaging outputs.
Screening & Assay Development
- Prepares validated in vivo models for downstream therapeutic screening of metabolic modulators.
- Standardizes imaging and histological quantification for reproducible, quantitative assay outputs.
- Enables robust comparison of compound efficacy based on dynamic metabolic readouts.
Translational & Preclinical Research
- Aligns imaging biomarkers with histological endpoints for translational biomarker development.
- Supports continuity from discovery through preclinical validation by linking in vivo and ex vivo data.
- Informs risk-adjusted advancement decisions based on early metabolic response profiles.
Pipeline & Workflow Integration
This method integrates into the discovery-to-preclinical continuum by enabling early, quantitative assessment of therapeutic impact on tumor metabolism in vivo.
- Discovery Biology: Provides hypothesis testing for metabolic pathway targeting and mechanistic de-risking.
- Screening: Delivers reproducible, quantitative imaging and histology outputs for compound evaluation.
- Analytics: Offers standardized measurements of glucose uptake and biomarker expression for cross-condition comparison.
- Translational Research: Bridges in vivo imaging with ex vivo biomarker quantification for translational alignment.
- Enterprise Reuse: Establishes a reusable platform for evaluating metabolic responses across therapeutic candidates.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in metabolic target validation.
- Operational Value: Enhances standardization, reproducibility, and scalability of imaging and histology workflows.
- Strategic Value: Improves go/no-go decisions and capital efficiency by providing early metabolic response data.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of metabolic pathway-targeted therapies.
Implementation Considerations
- Requires expertise in small animal imaging, radiotracer handling, and quantitative histology.
- Demands access to PET/CT instrumentation, dose calibrators, and morphometric analysis software.
- Necessitates strict standardization of animal handling, anesthesia, and fasting protocols for reproducibility.
- Adaptation across different genetic models or tumor types may require protocol optimization.
- Radioactivity handling imposes regulatory and safety requirements for laboratory operations.
Biopharma FAQs
Why does null hypothesis testing matter for PET/CT-based target validation?
Null hypothesis testing in PET/CT imaging enables objective assessment of whether targeted therapies induce significant metabolic changes in tumor models, supporting robust target validation. This statistical rigor underpins confidence in early discovery decisions and portfolio triage. Quantitative imaging outputs provide the necessary data for these analyses.
How does independent variable isolation fit the imaging workflow?
Isolating variables such as genotype, treatment, and animal handling ensures that observed metabolic changes in PET/CT imaging are attributable to the intervention under study. This control is critical for mechanistic de-risking and reliable interpretation of therapeutic impact in preclinical models.
What do quantitative dependent variable measurements enable in this protocol?
Quantitative measurements of glucose uptake and biomarker expression enable precise comparison of metabolic responses across treatment groups. These outputs support data-driven go/no-go decisions and facilitate cross-functional evaluation of therapeutic efficacy.
Why are replication requirements important for cross-functional collaboration?
Replication of imaging and histology procedures ensures reproducibility and reliability of metabolic response data, which is essential for cross-team validation and downstream translational research. Consistent protocols enable integration of findings across discovery and preclinical functions.
What statistical analysis capabilities are required before implementation?
Robust statistical analysis tools are needed to evaluate significance of metabolic changes, compare treatment effects, and validate biomarker correlations. These capabilities are foundational for interpreting PET/CT and histology data in a portfolio-relevant context.
![Visualization and Quantification of Brown and Beige Adipose Tissues in Mice using [18F]FDG Micro-PET/MR Imaging](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62460.jpg%3Fv%3D2026-08-11T08%253A27%253A22.161Z&w=384&q=75)